OKLAHOMA CITY, OK--(Marketwire - July 31, 2012) -
Cytovance® Biologics, a leading full-service contract manufacturer ("CMO") of mammalian and microbial biologics, announces Don Wuchterl as the new Senior Vice President of Manufacturing Operations.
"With over 20 years of experience in the biopharmaceutical industry, Don brings a wealth of knowledge and experience in clinical and commercial manufacturing," said Darren Head, President and Chief Executive Officer of Cytovance Biologics. "Don's expertise and leadership skills will be tremendous assets to the Company as we continue to enhance our manufacturing pipeline."
Specifically, Mr. Wuchterl's experience involved clinical and commercial GMP manufacturing in biologics, small molecule and peptides. He has extensive experience in the design, validation, start-up, licensure and operation of biologics facilities.
Prior to Cytovance, Mr. Wuchterl was the Director of Manufacturing at Dendreon's Immunotherapy Manufacturing facility in Union City, GA. In this capacity, he was integral in the construction, start-up, and licensure of the facility expanding Dendreon's manufacturing capacity for their flagship product "Provenge," the first immunotherapy approved by the FDA. Before Dendreon, Mr. Wuchterl held the position of Director of Manufacturing at Shire, Human Genetic Therapies. In this role, he was responsible for the end-user design and start-up of Shire's Lexington, Massachusetts Mammalian Cell Culture facility.
Mr. Wuchterl's experience in facility expansions is a plus to Cytovance that is in the process of increasing its overall manufacturing capabilities. This expansion is a result of an increase in existing and new client contracts.
Previous to Shire, Mr. Wuchterl held the position of Sr. Manufacturing Manager with Amgen on their fill/finish project in Co. Cork Ireland. Prior to this international post, Mr. Wuchterl held upstream and downstream manufacturing management positions at Amgen's large scale manufacturing facilities in Rhode Island and Colorado. Mr. Wuchterl also held positions of increasing responsibility with Biogen Idec and Roche.
Mr. Wuchterl holds a B.S. in Quality Engineering from Warren National University.
About Cytovance® Biologics
Cytovance® Biologics is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking and support services from its Oklahoma City state-of-the-art facilities.
Learn more about Cytovance Biologics at www.cytovance.com.